December 2023

KromaTid, SeQure Dx to Comarket Gene Editing Research Technologies

October 2023

KromaTiD Webinar Next Gen Cytogenetics: Finding Hidden Clues to Health and Disease

KromaTiD and Noble Life Sciences OEM Partnership Provides Comprehensive Genotoxicity Analysis

September 2023

KromaTiD Joins Scientist.coms IND Package Pipeline Program

July 2023

KromaTiD Launches dGH in-Site™ DNA Probes, Expanding Access for Cell and Gene Therapy Research Programs

May 2023

American Society of Cell & Gene Therapy (ASGCT) 2023, Booth 946

Multiplexed Editing without Chromosomal Rearrangements Using Epigenetic Editors

Automating the Analysis of Genomic Damage: Instability and Genotoxicity Using AI and Machine Learning

April 2023

Interview with KromaTiD CEO Nathan Wood, “Transitioning from Service to Product” on Life Science Marketing Radio with Chris Connor

March 2023

KromaTiD Launches dGH in-Site™ CAR-T Kit for TRAC & B2M Loci

January 2023

KromaTiD Launches PlasmidPros for Fast, Affordable Standard Plasmid Manufactruring

KromaTiD Announces Launch of Plasmid Manufacturing

October 2022

KromaTiD Webinar Series:
Track Genomic Stability and Localize Chromosone Rearrangements Using dGH SCREEN™

July 2022

KromaTiD Announces Launch of dGH™ Cell Prep Kit

May 2022

KromaTiD Announces Launch of Pinpoint FISH™ DNA Probes

April 2022

KromaTiD Webinar CRISPR Off Target Gene Editing  provided by GEN News April 27, 2022

KromaTiD GEN News Webinar Presentation Slides

February 2022

KromaTiD Inc. Announces the Launch of Cell Culture Services

January 2022

KromaTiD Announces Launch of KromaTiD Pinpoint FISH TP53/CEP17 Kit for synthetic oligonucleotide-based FISH assay.

September 2021

Dr. Chris Tompkins and Erin Cross Present Webinar for the Launch of dGH SCREEN™ for Unbiased Whole Genome Analysis of Chromosomal Structural Rearrangements

September 2021

Dr. Chris Tompkins and Erin Cross Present Webinar for the Launch of dGH SCREEN™ for Unbiased Whole Genome Analysis of Chromosomal Structural Rearrangements

May 2021

Chief Commercial Officer Dr. David Sebesta Presents at the 2021 Gene Therapy: Europe Virtual Conference

April 2021

KromaTiD Receives $2.0 Million of Growth Capital Investment from BroadOak Capital Partners

Chief Commercial Officer Dr. David Sebesta and Dr. Lauren Kinner-Bibeau Present Webinar on Single-Cell Measurements of Genomic Inserts and Transgenes

Applied Spectral Imaging and KromaTiD Announce Strategic Commercial Partnership

December 2020

KromaTiD and dGH in-Site are featured in Genetic Engineering & Biotechnology News

KromaTiD CCO, Dr. David Sebesta, presents at the 2020 Virtual NextGen Omics Series

October 2020

KromaTiD: Who We Are

September 2020

KromaTiD Announces the Appointment of Vic Myer, PhD to its Board of Directors

August 2020

KromaTiD Awarded Direct to Phase II SBIR Grant by the National Human Genome Research Institute

June 2020

KromaTiD Announces Launch of New Product, dGH In-Site™

December 2019

KromaTiD Announces the Appointment of David Brunel to its Board of Directors

September 2019

KromaTiD Highlighted in Denver Business Journal as Leader in Colorado Gene Editing Space

August 2019

KromaTiD Announces Closing of A Round Financing

July 2019

dGH Cell Culture Protocol Video

April 2019

Scientific Co-Founder Susan Bailey’s NASA ‘Twins Study’ Highlighted On:

• The New York Times 
• CBS
• The Today Show
• CNN
• NPR
• The Wall Street Journal

KromaTiD’s dGH Technology in April Issue of NASA Spinoff Magazine

March 2019

KromaTiD Announces Opening of New Corporate Headquarters

August 2018

KromaTiD Inc. is Awarded Fast-Track Small Business Innovation Research Grant

Read more about the SBIR grant on Genome Web.